Wall Street brokerages expect that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will post sales of $1.15 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Karyopharm Therapeutics’ earnings. The highest sales estimate is $2.46 million and the lowest is $50,000.00. Karyopharm Therapeutics reported sales of $1.53 million in the same quarter last year, which indicates a negative year-over-year growth rate of 24.8%. The firm is scheduled to issue its next earnings results on Thursday, March 21st.
On average, analysts expect that Karyopharm Therapeutics will report full year sales of $30.61 million for the current financial year, with estimates ranging from $30.10 million to $32.59 million. For the next fiscal year, analysts expect that the business will post sales of $21.67 million, with estimates ranging from $4.72 million to $45.98 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.88) by $0.09. Karyopharm Therapeutics had a negative net margin of 502.90% and a negative return on equity of 104.50%. The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.21 million.
A number of research analysts have issued reports on the stock. BidaskClub lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 29th. ValuEngine lowered shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, November 7th. Wedbush upgraded shares of Karyopharm Therapeutics from a “neutral” rating to an “outperform” rating and set a $19.00 price target on the stock in a research note on Friday, November 9th. Finally, B. Riley started coverage on shares of Karyopharm Therapeutics in a research note on Friday, November 30th. They set a “buy” rating and a $23.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Karyopharm Therapeutics has a consensus rating of “Buy” and an average target price of $21.90.
In other news, insider Sharon Shacham sold 12,500 shares of the stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $11.65, for a total value of $145,625.00. Following the sale, the insider now owns 726,010 shares in the company, valued at $8,458,016.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Kauffman sold 9,600 shares of the stock in a transaction on Monday, November 26th. The stock was sold at an average price of $11.00, for a total transaction of $105,600.00. Following the completion of the sale, the chief executive officer now owns 521,743 shares in the company, valued at approximately $5,739,173. The disclosure for this sale can be found here. Insiders sold 57,500 shares of company stock worth $636,231 in the last quarter. Company insiders own 13.26% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in shares of Karyopharm Therapeutics in the third quarter worth $195,000. Verition Fund Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the third quarter worth $242,000. Fox Run Management L.L.C. acquired a new stake in shares of Karyopharm Therapeutics in the third quarter worth $266,000. Metropolitan Life Insurance Co. NY boosted its holdings in Karyopharm Therapeutics by 38.9% during the second quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $277,000 after buying an additional 4,556 shares in the last quarter. Finally, Voya Investment Management LLC boosted its holdings in Karyopharm Therapeutics by 24.3% during the second quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock worth $317,000 after buying an additional 3,653 shares in the last quarter. Hedge funds and other institutional investors own 71.21% of the company’s stock.
Karyopharm Therapeutics stock traded down $0.08 during mid-day trading on Wednesday, reaching $10.09. 285,517 shares of the company traded hands, compared to its average volume of 529,138. Karyopharm Therapeutics has a fifty-two week low of $8.01 and a fifty-two week high of $21.71. The firm has a market capitalization of $621.04 million, a price-to-earnings ratio of -3.59 and a beta of 3.36.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Read More: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.